The effects of the synthetic @entity554 @entity11069 ( @entity11069 ) on @entity263 @entity3 in vivo were evaluated in the @entity19 prostate reconstitution (MPR) model. MPRs were produced by infection of either heterozygous (+/-) or nullizygous (-/-) @entity899 -mutant fetal prostatic epithelial cells with the recombinant retrovirus Zipras/myc 9. Previous studies have documented that loss of @entity899 function potentiates @entity3 in this model system. MPRs were grafted into homozygous (+/+) @entity899 male @entity19 , fed a @entity11069 containing diet or a control diet and maintained until the status of @entity5 progression dictated sacrifice. Under these experimental conditions, treatment with @entity11069 did not have a significant effect on @entity5 wet weight for either @entity899 +/- or @entity899 -/- MPRs. For, @entity899 +/- MPRs the animals fed the @entity11069 diet had a slight improvement in survival and a significant reduction in the number of mesenteric @entity3 (P = 0.0477, t-test). Notably, in @entity899 +/- MPRs the incidence of @entity3 to lumbar spine and sternum was 92% in the control animals compared to 54% in the @entity11069 treated animals (P = 0.035, chi2-test). In @entity899 -/- MPRs there was a trend toward a reduction in the number of soft tissue @entity3 to lung and liver in the @entity11069 group relative to the control diet group and a statistically significant reduction in the incidence of @entity3 to bone was demonstrated in that 50% of control animals versus 30% of @entity11069 treated @entity899 -/- animals harbored bone @entity3 (P = 0 < 0.05, chi2-test). Cell lines were established from portions of the @entity5 and from selected metastatic deposits in each experimental group. Clonal analysis, by retroviral integration pattern, indicated increased clonal diversity in both the @entity5 and @entity3 -derived cell lines from @entity11069 treated animals relative to the control animals. In vitro treatment with @entity11069 did not reveal discriminating differences between cell lines derived from @entity5 and bone @entity3 or control and treatment groups in regard to growth arrest or apoptotic responses. Overall these studies indicate limited anti- @entity5 and anti-metastatic activity in this highly aggressive in vivo @entity19 model of @entity263 , yet @entity11069 treatment significantly suppressed the development of bone @entity3 in @entity899 +/- and @entity899 -/- MPRs revealing a novel and potentially clinically useful activity of this @entity554 .

Dietary XXXX suppresses the development of bone @entity3 in vivo in a @entity19 model of @entity263 progression.

@entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer'] @entity19 :: ('10090', 'Species') :: ['mice', 'mouse'] @entity11069 :: ('MESH:D017313', 'Chemical') :: ['N-(4-hydroxyphenyl) retinamide', '4-HPR'] @entity899 :: ('22060(Tax:10090)', 'Gene') :: ['p53'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'primary tumors', 'primary tumor'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis', 'metastases'] @entity554 :: ('CHEBI:26537', 'Chemical') :: ['retinoid']
@entity11069 :: (MESH:D017313,Chemical) :: ['4-HPR']
